-
Mashup Score: 1What's coming in five years? FDA chief points to universal flu vaccine, new approval pathway - 8 hour(s) ago
When it comes to pharma innovation over the next several years, the heads of the FDA and European Medicines Agency are expecting quite a few transformational advances.
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
A groundbreaking new therapy that can almost entirely prevent HIV is days away from an FDA decision — but a mix of recent federal politics and historically slow launches may get in its way.
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
With HIV prevention under attack, how might Gilead’s new PrEP injection fare? https://t.co/DFeg5AlvuE
-
-
Mashup Score: 9Kennedy's vaccine doubts hinge on 'inert' placebos, but experts say he misunderstands the science - 4 day(s) ago
HHS Sec. Robert F. Kennedy’s vaccine skepticism and removal of CDC advisory panel members challenged by experts Plotkin, Offit & others who say he misunderstands placebo science.
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
Kennedy’s doubts over vaccine placebos don’t align with science, experts say https://t.co/0IOA9QsWBG
-
-
Mashup Score: 12Exclusive: Kennedy picks for vaccine advisory board were paid experts against Merck in civil cases - 4 day(s) ago
Two of HHS Secretary Robert F. Kennedy Jr.’s new appointees to the CDC’s vaccine advisory board have previously served as paid expert witnesses for plaintiffs suing drugmaker Merck over its HPV and MMR shots.
Source: Endpoints NewsCategories: General Medicine NewsTweet-
Pretty obvious what the implications are for vaccine makers. @endpts exclusive https://t.co/8GdjPBuNlN
-
-
Mashup Score: 5
Vaxart’s stock price shot up Wednesday after releasing new data in the same week that vaccine R&D is the focus of attention.
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
Vaxart shares rise after reporting norovirus vaccine data https://t.co/v3wYjKj5Nm
-
-
Mashup Score: 4FDA’s Makary says he wasn’t part of decision to gut ACIP, defers possible VRBPAC changes to Prasad - 6 day(s) ago
FDA Commissioner Marty Makary said he wasn’t involved in Robert F. Kennedy Jr.’s decision to fire every member of a key CDC expert panel that guides national vaccine policy.
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
FDA’s Makary says he wasn’t part of decision to gut ACIP, defers possible VRBPAC changes to Prasad https://t.co/ISc1kkyjkj
-
-
Mashup Score: 5Former HHS lawyer on Novavax delay: Mixing politics and approvals 'imperils' public health - 7 day(s) ago
The FDA’s infusion of a political appointee into the approval decision for Novavax’s Covid-19 vaccine
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
Former HHS lawyer criticizes politicization of Novavax vaccine decision - https://t.co/w7siXgGVZQ
-
-
Mashup Score: 2
The FDA approved Merck’s RSV antibody for babies, teeing up a rivalry with Sanofi and AstraZeneca’s Beyfortus.
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
Merck wins FDA approval for RSV antibody drug, making a hot market more competitive https://t.co/o3w0bRCZVd
-
-
Mashup Score: 0Sanofi leans into 'first-mover advantage' by shipping Beyfortus early, as RSV antibody market set to heat up - 8 day(s) ago
Sanofi to deliver RSV drug Beyfortus early before November season; faces potential competition from Merck’s clesrovimab awaiting FDA approval. Both are antibodies for infant protection.
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
Sanofi speeds up global shipping for Beyfortus as RSV antibody market set to heat up https://t.co/x96uuq2GXf
-
-
Mashup Score: 2GSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of corporate affairs - 11 day(s) ago
→ GSK has made a key hire for a crucial part of its business, appointing Sanjay Gurunathan as global head of vaccines and infectious disease R&D. Over the course of …
Source: Endpoints NewsCategories: General Medicine News, Infectious DiseaseTweet-
“GSK has made a key hire for a crucial part of its business, appointing Sanjay Gurunathan as global head of vaccines and infectious disease” https://t.co/ArL9m5z1c5
-
FDA chief Makary predicts a universal flu vaccine in next five years https://t.co/VMILOJhPMG